|
|
||||||||||
|
J Am Coll Cardiol, 2008; 51:810-815, doi:10.1016/j.jacc.2007.09.065 © 2008 by the American College of Cardiology Foundation |





* Department of Medicine, University of California at San Francisco, San Francisco, California
Division of Research, Kaiser Permanente of Northern California, Oakland, California
Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts.
Manuscript received July 2, 2007; revised manuscript received September 11, 2007, accepted September 17, 2007.
* Reprint requests and correspondence: Dr. Margaret C. Fang, 503 Parnassus Avenue, Box 0131, San Francisco, California 94143. (Email: mfang{at}medicine.ucsf.edu).
Objectives: We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF)–related thromboembolism in a large community-based cohort.
Background: Risk schemes can help target anticoagulant therapy for patients at highest risk for AF–related thromboembolism. We tested the predictive ability of 5 risk schemes: the Atrial Fibrillation Investigators, Stroke Prevention in Atrial Fibrillation, CHADS2 (Congestive heart failure, Hypertension, Age
75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack) index, Framingham score, and the 7th American College of Chest Physicians Guidelines.
Methods: We followed a cohort of 13,559 adults with AF for a median of 6.0 years. Among non-warfarin users, we identified incident thromboembolism (ischemic stroke or peripheral embolism) and risk factors from clinical databases. Each scheme was divided into low, intermediate, and high predicted risk categories and applied to the cohort. Annualized thromboembolism rates and c-statistics (to assess discrimination) were calculated for each risk scheme.
Results: We identified 685 validated thromboembolic events that occurred during 32,721 person-years off warfarin therapy. The risk schemes had only fair discriminating ability, with c-statistics ranging from 0.56 to 0.62. The proportion of patients assigned to individual risk categories varied widely across the schemes. The proportion categorized as low risk ranged from 11.7% to 37.1% across schemes, and the proportion considered high risk ranged from 16.4% to 80.4%.
Conclusions: Current risk schemes have comparable, but only limited, overall ability to predict thromboembolism in persons with AF. Recommendations for antithrombotic therapy may vary widely depending on which scheme is applied for individual patients. Better risk stratification is crucially needed to improve selection of AF patients for anticoagulant therapy.
| ||||||||
Related Articles
J. Am. Coll. Cardiol. 2008 51: 816-817.
J. Am. Coll. Cardiol. 2008 51: A23-A24.
This article has been cited by other articles:
![]() |
Stroke Risk in Atrial Fibrillation Working Group Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation Stroke, June 1, 2008; 39(6): 1901 - 1910. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Weintraub Predicting Thromboembolism and Selecting Patients for Anticoagulant Therapy in Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 816 - 817. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |